News

Congratulate ProteLight got the title of “the most potential seed corporation” granted by 2014 EY Fudan in China

2014-09-23

The most Potential Corporation Award Ceremony of the Fourth Ernst & Young Fudan in China was held on September 16, 2014, in Shanghai. This selection was hold jointly by Ernst & Young, one of the world’s four largest accounting firms in economic area, and School of Management, Fudan University’s, one of the top universities. After expert team’s careful assessment and strict selection, the winning companies were selected out in the end.

Previous article

Warmly congratulations to establishment of Hartmut Michel Institute of (Jiangyin) Biomedical Research

Next article

Two New Drugs of National Category 1.1 Got Clinical Acceptance Notification

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China